RADX
OtherRadiopharm Theranostics Limited American Depositary Shares
$4.25-0.34 (-7.41%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving RADX Today?
No stock-specific AI insight has been generated for RADX yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$34M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume63K
Avg Volume (10D)—
Shares Outstanding7.9M
RADX News
20 articles- Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online ViewingYahoo Finance·Apr 29, 2026
- Radiopharm Theranostics Highlights Phase 1 Pipeline, Eyes June RAD 101 Data at DB ConferenceMarketbeat·Apr 29, 2026
- Radiopharm Theranostics ADR (RADX): Inside the Clinical ProgramsYahoo Finance·Apr 28, 2026
- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026Yahoo Finance·Apr 23, 2026
- Radiopharm Theranostics Reports Business UpdateGlobeNewswire Inc.·Apr 23, 2026
- Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026Yahoo Finance·Apr 20, 2026
- Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain MetastasesYahoo Finance·Apr 16, 2026
- Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical TrialGlobeNewswire Inc.·Apr 8, 2026
- Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.GlobeNewswire Inc.·Apr 7, 2026
- RADX: RAD 101 Phase IIb Interim AnalysisYahoo Finance·Apr 6, 2026
- Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate CancerGlobeNewswire Inc.·Mar 27, 2026
- Inside Biotech: Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trialProactive Investors·Mar 26, 2026
- Radiopharm Theranostics Shares RAD101 Phase IIb Update: 90% Hit Primary Endpoint in Brain Mets StudyMarketbeat·Mar 25, 2026
- Radiopharm Theranostics Highlights 90% Positive RAD101 Interim Data, Eyes Phase III FDA TalksMarketbeat·Mar 25, 2026
- Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain MetastasesYahoo Finance·Mar 24, 2026
- AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)Yahoo Finance·Feb 24, 2026
- Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)Yahoo Finance·Feb 24, 2026
- RADX Fiscal 1H:26 Activity and Cash FlowsYahoo Finance·Feb 2, 2026
- Radiopharm Theranostics Reports Half-Year Financial Results and Business UpdatesYahoo Finance·Jan 28, 2026
- Zacks Small Cap Research Best Ideas for 2026Yahoo Finance·Jan 26, 2026
All 20 articles loaded
Price Data
Open$4.45
Previous Close$4.59
Day High$4.50
Day Low$4.30
52 Week High—
52 Week Low—
Fundamentals
Market Cap$34M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume63K
Avg Volume (10D)—
Shares Outstanding7.9M
About Radiopharm Theranostics Limited American Depositary Shares
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
Company Details
Security Type—
ExchangeNASDAQ
Currency—
Round Lot—
SIC—
CIK—
Composite FIGI—
Share Class FIGI—